Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of sirukumab in adults with severe or critical COVID-19 has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical COVID-19

Drugs mentioned

• Sirukumab (sirukumab)

Snippet

Sponsor: Janssen Pharmaceutica N.V., Belgium | Conditions: Critical Confirmed Coronavirus Disease (COVID)-19 | Phase 2 | Status: COMPLETED | Results posted: 2022-06-21